Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
In the present study, DNA from 27 grade I and grade II pediatric gliomas, including ganglioglioma, desmoplastic infantile ganglioglioma, dysembryoplastic neuroepithelial tumor, and pleomorphic xanthoastrocytoma was analyzed using the Illumina 610K Beadchip SNP-based oligonucleotide array. Several consistent abnormalities, including gain of chromosome 7 and loss of 9p21 were observed. Based on our previous studies, in which we demonstrated BRAF mutations in 3 gangliogliomas, 31 tumors were screened for activating mutations in exons 11 and 15 of the BRAF oncogene or a KIAA1549-BRAF fusion product. There were no cases with a KIAA1549-BRAF fusion. A BRAF V600E mutation was detected in 14 of 31 tumors, which was not correlated with any consistent pattern of aberrations detected by the SNP array analysis. Tumors were also screened for mutations in codon 132 in exon 4 of IDH1, exons 2 and 3 of KRAS, and exons 2-9 of TP53. No mutations in KRAS or TP53 were identified in any of the samples, and there was only 1 IDH1 R132H mutation detected among the sample set. BRAF mutations constitute a major genetic alteration in this histologic group of pediatric brain tumors and may serve as a molecular target for biologically based inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
BrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
Jones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 944
The Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping
Peiffer, D. A., Le, J. M., Steemers, F. J., Chang, W., Jenniges, T., Garcia, F., Haden, K., Li, J., Shaw, C. A., Belmont, J., et al. (2006) · Genome Research · doi:10.1101/gr.5402306 · Cited by 519
Forshew, T., Tatevossian, R. G., Lawson, A. R., Ma, J., Neale, G., Ogunkolade, B. W., Jones, T. A., Aarum, J., Dalton, J., Bailey, S., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2558 · Cited by 304
Start, R. D. (2000) · Histopathology · doi:10.1046/j.1365-2559.2000.01097.x · Cited by 304
Expression of p53 and Prognosis in Children with Malignant Gliomas
Pollack, I. F., Finkelstein, S. D., Woods, J., Burnham, J., Holmes, E. J., Hamilton, R. L., Yates, A. J., Boyett, J. M., Finlay, J. L., & Sposto, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012224 · Cited by 281
Korshunov, A., Meyer, J., Capper, D., Christians, A., Remke, M., Witt, H., Pfister, S., von Deimling, A., & Hartmann, C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0550-z · Cited by 279
BRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
Sievert, A. J., Jackson, E. M., Gai, X., Hakonarson, H., Judkins, A. R., Resnick, A. C., Sutton, L. N., Storm, P. B., Shaikh, T. H., & Biegel, J. A. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00225.x · Cited by 255
Self-citationMAP'ing CNS Development and Cognition: An ERKsome Process
Samuels, I. S., Saitta, S. C., & Landreth, G. E. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.001 · Cited by 202
Prevalence of Priapism in Children and Adolescents With Sickle Cell Anemia
Mantadakis, E., Cavender, J. D., Rogers, Z. R., Ewalt, D. H., & Buchanan, G. R. (1999) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199911000-00013 · Cited by 183
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas
Knobbe-Thomsen, C. B., REIFENBERGER, J., & Reifenberger, G. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0929-9 · Cited by 156
Prayson, R. A., Khajavi, K., & Comair, Y. G. (1995) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199507000-00005 · Cited by 154
Juvenile Myelomonocytic Leukemia and Noonan Syndrome
Choong, K. L. M., Freedman, M. H., Chitayat, D. A., Kelly, E., Taylor, G. P., & Zipursky, A. (1999) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199911000-00014 · Cited by 150
Weber, R. G., Hoischen, A., Ehrler, M., Zipper, P., Kaulich, K., Blaschke, B., Becker, A. J., Weber‐Mangal, S., Jauch, A. T., Radlwimmer, B., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209851 · Cited by 118
Mutation analysis of B-RAF gene in human gliomas
Basto, D., Trovisco, V., Lopes, J. M., Martins, A. M., Pardal, F., Soares, P., & Reis, R. M. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0936-x · Cited by 90
Mutational analysis of TSC1 and TSC2 genes in gangliogliomas
Becker, A. J., Löbach, M., Klein, H., Normann, S., Nöthen, M. M., von Deimling, A., Mizuguchi, M., Elger, C. E., Schramm, J., Wiestler, O. D., et al. (2001) · Neuropathology and Applied Neurobiology · doi:10.1046/j.0305-1846.2001.00302.x · Cited by 85
Lack of Association between BRAF Mutation and MAPK ERK Activation in Melanocytic Nevi
Uribe, P., Andrade, L., & González, S. (2005) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700011 · Cited by 81
Mixed dysembryoplastic neuroepithelial tumor and ganglioglioma
Hirose, T., & Scheithauer, B. W. (1998) · Acta Neuropathologica · doi:10.1007/s004010050852 · Cited by 62
A review of the cytogenetics of 58 pediatric brain tumors
Roberts, P., Chumas, P., Picton, S. V., Bridges, L., Livingstone, J., & Sheridan, E. G. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00483-6 · Cited by 48
Shimbo, Y., Takahashi, H., Hayano, M., Kumagai, T., & Kameyama, S. (1997) · PubMed · Cited by 39
Yin, X.-L., Hui, A. B., Pang, J. C., Poon, W. S., & Ng, H. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00611-2 · Cited by 37
Nichols, K. E., Heath, J. A., Friedman, D., Biegel, J. A., Ganguly, A. A., Mauch, P., & Diller, L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.042 · Cited by 37
Self-citationWójcik, P., Kulig, J., Okoń, K., Zazula, M., Moździoch, I., Niepsuj, A., & Stachura, J. (2008) · PubMed · Cited by 36
Cytogenetic findings in a pleomorphic xanthoastrocytoma
Sawyer, J. R., Roloson, G. J., Chadduck, W. M., & Boop, F. A. (1991) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(91)90081-5 · Cited by 33
Yin, X.-L., Hui, A. B., Liong, E. C., Ding, M., Chang, A. R., & Ng, H. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00512-x · Cited by 32
SNP-CGH technologies for genomic profiling of LOH and copy number
Peiffer, D. A., & Gunderson, K. L. (2006) · Cited by 3
Cited by
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
Glioma Subclassifications and Their Clinical Significance
Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0519-x · Cited by 812
“Pilocytic astrocytomas make up 20% of pediatric brain tumors and appear to have about a 9% rate of BRAF mutation [65].”
BackgroundDeclining childhood and adolescent cancer mortality
Smith, M. A., Altekruse, S. F., Adamson, P. C., Reaman, G. H., & Seibel, N. L. (2014) · Cancer · doi:10.1002/cncr.28748 · Cited by 542
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas
Ryall, S., Zapotocky, M., Fukuoka, K., Nobre, L., Guerreiro Stucklin, A., Bennett, J., Siddaway, R., Li, C., Pajovic, S., Arnoldo, A., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.011 · Cited by 474
Self-citationQaddoumi, I., Orisme, W., Wen, J., Santiago, T., Gupta, K., Dalton, J. D., Tang, B., Haupfear, K., Punchihewa, C., Easton, J., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1539-z · Cited by 409
Metadata
- Authors
- Dougherty, M. J., Santi, M., Brose, M. S., Ma, C., Resnick, A. C., Sievert, A. J., Storm, P. B., & Biegel, J. A.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-02-14
- Volume
- 12
- Issue
- 7
- Pages
- 621-630
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2124664680
- Cited by
- 324
- References
- 34
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.